Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphomaMetabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug Vatalanib.Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trialsVatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®).Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
P921
Q33406444-4B6D7718-3061-4F9B-8598-259F718AAAE2Q34553316-EF842466-7CCD-46A8-91EA-B445FF7A0E29Q34570873-9F03B54A-22CA-4445-AC51-E6A90BFA79C2Q35703129-F65AA449-DD73-41DA-9B18-5428078A06D8Q35786901-F5C31D3C-11D0-4939-AE8D-876FEEB62147Q36287999-61DE6127-C6C2-4E57-9DF7-DE465582A19EQ36652941-99212568-56A1-4B22-9757-93D6727E2EBCQ37170610-F71E6B48-BE40-475D-8A1F-5127AEBDF298Q38849843-D3C0CF0F-ABCD-426E-AD3A-BA95E41ECC87Q38945564-F0D938C0-C46B-4185-B08B-FBBB4E8B0638Q39198025-D40237D3-02FA-4273-968D-B671ED2A3223Q45236702-9DF06718-1ADA-4CC6-B58E-6E3F8BA501B0Q54383059-E23ADD58-B511-4BE9-B93B-20D5D2A5188CQ59312912-A1A70D93-2173-4D86-A948-D49AB4CF674D
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Vatalanib
@sh
Vatalanib
@sr
vatalanib
@en
type
label
Vatalanib
@sh
Vatalanib
@sr
vatalanib
@en
altLabel
1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate
@en
CGP 79787
@en
CGP-7978
@en
CGP-79787
@en
CGP79787
@en
N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine
@en
N-(p-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine
@en
PTK 787
@en
PTK-787
@en
PTK/ZK
@en
prefLabel
Vatalanib
@sh
Vatalanib
@sr
vatalanib
@en
P129
P486
P592
P6366
P661
P662
P665
P683
P129
P1579
P2067
346.098524
P2275
vatalanib
@en
P231
212141-54-3
P233
C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)Cl)CC4=CC=NC=C4
P234
1S/C20H15ClN4/c21-15-5-7-16(8- ...... 12-10-14/h1-12H,13H2,(H,23,25)
P235
YCOYDOIWSSHVCK-UHFFFAOYSA-N
P274
C₂₀H₁₅ClN₄
P3117
DTXSID2046919